Holen Sie sich die Stockscreener-App
9.22
2.64%
-0.25
Handel nachbörslich:
9.22
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt GRFS?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$9.47
Offen:
$9.22
24-Stunden-Volumen:
1.64M
Relative Volume:
1.44
Marktkapitalisierung:
$6.26B
Einnahmen:
$7.42B
Nettoeinkommen (Verlust:
$182.73M
KGV:
31.97
EPS:
0.2884
Netto-Cashflow:
$709.16M
1W Leistung:
-1.07%
1M Leistung:
+6.59%
6M Leistung:
+19.74%
1J Leistung:
-2.85%
1-Tages-Spanne:
$9.15
$9.44
1-Wochen-Bereich:
$9.0395
$9.75
52-Wochen-Spanne:
$5.3001
$12.15
Grifols Sa Adr Stock (GRFS) Company Profile
Vergleichen Sie GRFS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| GRFS | 9.22 | 6.26B | 7.42B | 182.73M | 709.16M | 0.2884 |
| LLY | 727.20 | 683.37B | 40.86B | 8.37B | -2.28B | 5.4193 |
| NVO | 99.81 | 446.14B | 39.36B | 13.79B | 9.83B | 2.4077 |
| JNJ | 154.77 | 353.35B | 87.70B | 14.68B | 19.03B | 13.47 |
| ABBV | 166.28 | 293.80B | 55.53B | 5.12B | 15.62B | 3.65 |
| MRK | 96.56 | 242.49B | 63.17B | 12.15B | 14.84B | 1.80 |
Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-04-12 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-16 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2023-01-18 | Hochstufung | Jefferies | Hold → Buy |
| 2022-04-08 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-11-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-10-19 | Herabstufung | Barclays | Overweight → Underweight |
| 2021-10-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-06-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2021-04-20 | Eingeleitet | Deutsche Bank | Hold |
| 2021-03-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-03-11 | Hochstufung | HSBC Securities | Hold → Buy |
| 2020-10-01 | Hochstufung | Citigroup | Sell → Neutral |
| 2020-06-09 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-06-09 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-03-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-06-27 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-02-08 | Herabstufung | Berenberg | Buy → Hold |
| 2018-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2018-06-01 | Eingeleitet | Barclays | Overweight |
| 2017-10-31 | Eingeleitet | Citigroup | Buy |
| 2017-06-30 | Herabstufung | Goldman | Buy → Neutral |
| 2017-04-06 | Eingeleitet | BofA/Merrill | Buy |
| 2017-01-03 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2016-02-09 | Hochstufung | Berenberg | Hold → Buy |
| 2016-01-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2015-12-02 | Herabstufung | HSBC Securities | Buy → Hold |
| 2015-11-20 | Herabstufung | Berenberg | Buy → Hold |
| 2015-04-28 | Herabstufung | Berenberg | Buy → Hold |
Alle ansehen
Grifols Sa Adr Aktie (GRFS) Neueste Nachrichten
Infectious Disease Diagnostics Market to Reach USD 43.09 Billion by 2031 | SkyQuest Technology - Benzinga
Is it possible to buy Grifols SA ADR(GRFS) shares at a good price now? - US Post News
Grifols SA ADR (GRFS)’s Day in Review: Closing at 8.58, Down by -0.12 - The Dwinnex
RFID Kanban Systems Market Forecast to Reach $9.53 Billion by 2030 - GlobeNewswire Inc.
A Look at Grifols SA ADR (GRFS) Shares in the Recent Past Indicates Growth - SETE News
Cboe Global Markets Inc. (AMEX: CBOE): Getting A Free Pass? - Stocks Register
It is Poised to be a Bull Market for Grifols SA ADR (GRFS) - SETE News
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
Examining Grifols SA ADR (GRFS) stock is warranted - US Post News
Are Grifols SA ADR’shares a good deal? - US Post News
Financial Health Report: Grifols SA ADR (GRFS)’s Ratios Tell a Tale - The Dwinnex
Was anything negative for Grifols SA ADR (GRFS) stock last session? - US Post News
Ratio Review: Analyzing Grifols SA ADR (GRFS)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
GRFS’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
How does Grifols SA ADR (GRFS) change from a tortoise to a hare? - SETE News
Mexico Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
The Significance of Moving Averages in Grifols SA ADR Inc. (GRFS) Price Performance - The InvestChronicle
Have you been able to find a good deal on Grifols SA ADR’s shares? - US Post News
Closing Figures: Grifols SA ADR (GRFS)’s Negative Finish at 8.41, Down -1.87 - The Dwinnex
A History of Outperforming Analyst Forecasts and Beating the Odds: Grifols SA ADR (GRFS) - SETE News
Analytical Overview: Grifols SA ADR (GRFS)’s Ratios Tell a Financial Story - The Dwinnex
Investing in Grifols SA ADR (GRFS) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Grifols Class B stock falls as Brookfield reportedly seeks lower price - MSN
Grifols Class B stock discounted by Brookfield (NASDAQ:GRFS) - Seeking Alpha
An analyst sees good growth prospects for Grifols SA ADR (GRFS) - SETE News
Grifols SA ADR [GRFS] Is Currently 1.11 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Grifols SA ADR (GRFS)’s Market Momentum: Closing Strong at 9.00, Up 2.74 - The Dwinnex
Grifols SA ADR (GRFS) looking to reclaim success with recent performance - SETE News
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
Is the Grifols SA ADR (NASDAQ:GRFS) stock an investment opportunity? - US Post News
Get in on Grifols SA ADR’s (GRFS) buy-in window today! - SETE News
Grofols stock gains as Brookfield eyes takeover (NASDAQ:GRFS) - Seeking Alpha
Market Update: Grifols SA ADR (GRFS) Sees Positive Movement, Closing at 7.18 - The Dwinnex
XPeng Inc. Sponsored ADR (XPEV) Laps the Stock Market: Here's Why - Yahoo Finance
How did Grifols SA ADR (GRFS) fare last session? - US Post News
Ratios Revealed: Decoding Grifols SA ADR (GRFS)’s Financial Health - The Dwinnex
Grifols SA ADR: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Are Investors Inclined To Sell Their Bath & Body Works Inc (NYSE: BBWI) Holdings? - Stocks Register
Does Uranium Royalty Corp (NASDAQ: UROY) Still Need To Convince Analysts? - Stocks Register
What Do Wall Street Analysts Think About Tetra Technologies, Inc. (NYSE: TTI) Stock? - Stocks Register
What Did We Find About Insider Trading At Monster Beverage Corp. (NASDAQ: MNST)? - Stocks Register
The growth track for Grifols SA ADR (GRFS) has changed recently - SETE News
India Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
Investing in Grifols SA ADR (GRFS) might be a great opportunity, but the stock is a bit overvalued - US Post News
Validea Joseph Piotroski Strategy Daily Upgrade Report8/6/2024 - Nasdaq
Grifols SA ADR’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
Our Attention Has Been Attracted to Grifols SA ADR (NASDAQ:GRFS) - US Post News
Grifols revises past financial records with equity value drop of $494 mln - Marketscreener.com
Grifols SA ADR (GRFS) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
You might want to take a look at Grifols SA ADR (GRFS) now - SETE News
A stock that deserves closer examination: Grifols SA ADR (GRFS) - US Post News
Finanzdaten der Grifols Sa Adr-Aktie (GRFS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.03%
1.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):